MicroRNA Biomarkers of Covid-19 Severity (miRCOVID)


The aim of this project is to apply our expertise on RNA biomarkers to identify circulating microRNAs (miRNAs) able to predict COVID-19 severity. This project responds to the medical need to identify patients at high risk of developing cardiovascular and/or inflammatory complications SARS-CoV-2 infection. The levels of inflammatory and cardiac miRNAs will be measured in plasma samples collected from 100 patients from the Luxembourg Predi-COVID study. The ability of those miRs to predict disease severity will be determined based on symptoms observed during a 3 week period.


This pilot study is in line with the national research priorities, but also with the research priorities defined by the WHO's Roadmap for Coordinated Global Research and by the European Commission. It is the initial phase of a large international multi-center study conducted with the members of the COVID-19 Task Force of the EU-CardioRNA COST Action. The call for this cooperative action was published in May 2020 in the European Heart Journal.

Financial support

This project is included in the Luxembourg COVID-19 Task Force and financed for 6 months by the FNR- Fonds National de la Recherche du Luxembourg.

For more info

• Yvan Devaux, PhD - CVRU Group Leader

• Mélanie VausortResearch Engineer